SUMMARY
For the psychiatrist, lithium is an effective drug for both the treatment and prophylaxis of bipolar
disorder. The molecular mechanisms underlying its therapeutic actions have not yet been fully
explained. The effects of lithium on a number of enzymes and biological processes have been
studied. Inositol monophosphatase and glycogen synthase kinase-3 (GSK-3) have been suggested
as the relevant intracellular targets for lithium action. The discovery of the role of GSK-3, the Wnt
signalling system, and the anti-apoptotic factor Bcl-2 has led to the suggestion that there could be
a therapeutic use for lithium in neurodegenerative disorders, such as Alzheimer's disease.
KEY WORDS
bipolar disorder; Alzheimer's disease; inositol monophosphatase; glycogen synthase kinase-3; programmed cell death
REFERENCES
Alda M, Grof P, Grof E et al.: Mode of
inheritance in families of patients with lithiumresponsive
affective disorders. Acta Psychiatr
Scand 90:304-310, 1994.
Alda M, Grof E, Cavazzoniet P al.: Autosomal
recessive inheritance of affective disorders in
families of responders to lithium prophylaxis? J
Affect Disord 44:153-157, 1997.
Allison JH and Stewart MA: Reduced brain
inositol in lithium-treated rats. Nature 33:267-268, 1971.
Atack JR: Inositol monophosphatase inhibitors: a
novel treatment for bipolar disorder? Biol
Psychiatry 37:761-763, 1995.
Avissar S, Schreiber G, Danon A, Belmaker
RH: Lithium inhibits adrenergic and cholinergic
increases in GTP binding in rat cortex. Nature
331:440-442, 1988.
Bauer M, Forsthoff A, Baethge C et al.: Lithium
augmentation therapy in refractory depression-Update 2002. Eur Arch Clin Neurosci 253:132-139, 2003.
Berridge MJ, Downes CP, Hanley MR: Lithium
amplifies agonist-dependent phosphatidylinositol
responses in brain and salivary glands.
Biochem J 206:587-595, 1982.
Berridge MJ, Downes CP, Hanley MR: Neural
and developmental actions of lithium: a unifying
hypothesis. Cell 59:411-419, 1989.
Berridge MJ and Irvine RF: Inositol
trisphosphate, a novel second messenger in
cellular signal transduction. Nature 312:315-321, 1984.
Berry GT, Buccafusca R, Greer JJ,
Eccleston E: Phosphoinositide deficiency due to
inositol depletion is not a mechanism of lithium
action in brain. Mol Genet Metab 82:87-92, 2004.
Bhat RV, Budd Haeberlein SL, Avila J:
Glycogen synthase kinase 3: a drug target for
CNS therapies. J Neurochem 89:1313-1317, 2004.
Bone R, Springer JP, Atack JR: Structure of
inositol monophosphatase the putative target of
lithium therapy. Proc Natl Acad Sci USA 89:10031-10035, 1992.
Bone R, Frank L, Springer JP, Atack JR:
Structural studies of metal binding by inositol
monophosphatase. Biochemistry 33:9468-9476, 1994.
Bunney WE, Pert A, Rosenblatt J, Pert CB,
Gallaper D: Mode of action of lithium. Some
biological considerations. Arch Gen Psychiatry
36:898-901, 1979.
Cade J: Lithium salts in the treatment of psychotic
excitement. Med J Aust 2:349-352, 1949.
Cadigan K.M. and Nusse R.: Wnt signaling: a
common theme in signal development. Genes
Dev 11:3286-3305, 1997.
Chen DF, Schneider GE, Martinou JC,
Tonegawa S: Bcl-2 promotes regeneration of
severed axons in mammalian CNS. Nature 385:434-439, 1997.
Dajani R, Fraser E, Roe SM et al.: Crystal
structure of glycogen synthase kinase 3 beta:
structural basis for phosphate-primed substrate
specificity and autoinhibition. Cell 105:721-732, 2001.
Davis JM and Fann WE: Lithium. Ann Rev
Pharmacol 11:285-302, 1971.
De Ferrari GV, Chacon MA, Barria MI et al.:
Activation of Wnt signaling rescues
neurodegeneration and behavioral impairments
induced by beta-amyloid fibrils. Mol Psychiatry
8:195-208, 2003.
Dehpour AR, Emamian ES, Ahmadi-Abhari
SA, Azizabadi-Farahani M: The lithium ratio
and the incidence of side effects. Prog
Neuropsychopharmacol Biol Psychiatry 22:959-970, 1998.
Dreno B, Chosidow O, Revuz J, Moyse D: The
study investigator group. Lithium gluconate 8%
vs ketoconazole 2% in the treatment of
seborrhoeic dermatitis: a multicentre,
randomized study. Br J Dermatol 148:1230-1236, 2003.
Drummond AH: Lithium affects G protein
receptor coupling. Nature 331:388, 1988.
Eldar-Finkelman H: Glycogen synthase kinase 3:
an emerging therapeutic target. Trends Mol
Med 8:126-132, 2002.
Frost RE and Messiha FS: Clinical uses of
lithium salts. Brain Res Bull 11:219-231, 1983.
Gallicchio VS: Transport of the lithium ion. In:
Bach RO and Gallicchio VC (eds.): Lithium
and cell physiology. Springer Verlag 1990, pp. 47-57.
Geisler A and Mork A: The interaction of lithium
with magnesium-dependent enzymes. In: In:
Bach RO and Gallicchio VC (eds.): Lithium
and Cell Physiology. Springer Verlag 1990, pp. 125-136.
Gomez-Ramos A, Smith MA, Perry G, Avila J:
Tau phosphorylation and assembly. Acta
Neurobiol Exp (Wars) 64:33-39, 2004.
Gould TD, Zarate CA, Manji HK: Glycogen
synthase kinase-3: a target for novel bipolar
disorder treatments. J Clin Psychiatry 65:10-21, 2004a.
Gould TD, Quiroz JA, Singh J, Zarate CA,
Manji HK: Emerging experimental therapeutics
for bipolar disorder: insights from the molecular
and cellular actions of current mood stabilizers.
Mol Psychiatry 9:734-755, 2004b.
Grof P, Alda M, Grof E, Zvolsky P, Walsh M:
Lithium response and genetics od affective
disorders. J Affect Disord 32:85-95, 1994.
Grof P, Hux M, Grof E, Arato M: Prediction of
response to stabilizing lithium treatment.
Pharmacopsychiat 16:195-200, 1983.
Hallcher LM and Sherman WR: The effects of
lithium ion and other agents on the activity of
myo-inositol-1-phosphatase from bovine brain.
J Biol Chem 255:10896-10901, 1980.
Harvey BH, Meyer CL, Gallichio VS,
Manji HK: Lithium salts in AIDS and AIDS-related
dementia. Psychopharmacol Bull 36:5-26, 2002.
Harwood AJ: Life, the universe and development.
Current Biol 10:R116-R119, 2000.
Hedgepeth C, Conrad L, Zhang Z et al.:
Activation of the Wnt signaling pathway: a
molecular mechanism for lithium action.
Develop Biol 185:82-91, 1997.
Hong M, Chen DC, Klein P, Lee VM: Lithium
reduces tau phosphorylation by inhibition of
glycogen synthase kinase-3. J Biol Chem 272:25326-25332, 1997.
Johnson CD, Puntis M, Davidson N, Todd S,
Bryce R: Randomized, dose-finding phase III
study of lithium gamolenate in patients with
advanced pancreatic adenocarcinoma. Br J
Surg 88, 662-668, 2001.
Johnson FN, Cade JFJ: The historical
background to lithium research and therapy. In:
Johnson FN (ed.): Lithium research and therapy, Academic Press Inc. (London) 1975, pp. 9-22.
Khachaturian ZS: An overview of Alzheimer's
disease research. Am J Med 104:26S-31S, 1998.
Klein PS and Melton DA: A molecular
mechanism for the effect of lithium on
development. Proc Natl Acad Sci USA 93:8455-8459, 1996.
Koong SS, Reynolds JC, Movius EG et al.:
Lithium as a potential adjuvant to 131I therapy
of metastatic, well differentiated thyroid
carcinoma. J Clin Endocrinol Metab 84:912-916, 1999.
Lenox R and Wang HLE: Molecular basis of
lithium action: Integration of lithium- responsive
signaling and gene expression networks. Molec
Psychiatry 8:135-144, 2003.
Leroy K, Boutajangout A, Authelet M et al.: The
active form of glycogen synthase kinase-3beta is
associated with granulovacuolar degeneration in
neurons in Alzheimer's disease. Acta
Neuropathol 103:91-99, 2002.
Levy-Lahad E, Wasco W, Poorkaj P et al.:
Candidate gene for the chromosome 1 familial
Alzheimer's disease locus. Science 269:973-977, 1995.
Liu SJ, Zhang AH, Li HL et al.: Overactivation
of glycogen synthase kinase-3 by inhibition of
phosphoinositol-3 kinase and protein kinase C
leads to hyperphosphorylation of tau and
impairment of spatial memory. J Neurochem
87:1333-1344, 2003.
Lovestone S, Davis DR, Webster MT et al.:
Lithium reduces tau phosphorylation: effects in
living cells and in neurons at therapeutic
concentrations. Biol Psychiatry 45:995-1003, 1999.
Manji HK and Lenox RH: Long-term action of
lithium: a role for transcriptional and
posttranscriptional factors regulated by protein
kinase C. Synapse 16:11-28, 1994.
Manji HK, Potter WZ, Lenox RH: Signal
transduction pathways. Molecular targets for
lithium's actions. Arch Gen Psychiatry 52:531-543, 1995.
Manji HK, Moore GJ, Chen G: Lithium up-regulates
the cytoprotective protein Bcl-2 in the
CNS in vivo: a role for neurotrophic and
neuroprotective effects in manic depressive
illness. J Clin Psychiatry 61, Suppl 9:82-96, 2000.
Miller JR, Hocking AM, Brown JD, Moon
RT: Mechanism and function of signal
transduction by the Wnt/beta-catenin and
Wnt/Ca2+ pathways. Oncogene 18:7860-7872, 1999.
Morgan TH: The relation between normal and
abnormal development of the embryo of the frog,
as determined by the effect of lithium chloride in
solution. Arch Entwickl 16:691-716, 1902.
Mudher A, Shepherd D, Newman TA et al.:
GSK-3beta inhibition reverses axonal transport
defects and behavioural phenotypes in
Drosophila. Mol Psychiatry 9:522-530, 2004.
Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J: Lithium inhibits Alzheimer's diseaselike
tau protein phosphorylation in neurons.
FEBS Lett 411:183-188, 1997.
Murayama M, Tanaka S, Palacino J et al.: Direct
association of presenilin 1 with beta-catenin.
FEBS Lett 433:73-77, 1998.
Nieoullon A: Alzheimer's disease: neurobiological
advances supporting proposals for new
therapeutical approaches. J Appl Biomed 2:123-130, 2004.
Norton B and Whaley LJ: Mortality of lithiumtreated
population. Br J Psychiatry 145:277-282, 1984.
O'Brien WT, Harper AD, Jove F et al.:
Glycogen synthase kinase-3beta
haploinsufficiency mimics the behavioral and
molecular effects of lithium. J Neurosci 24:6791-6798, 2004.
Pap M and Cooper GM: Role of glycogen
synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem
273:19929-19932, 1998.
Passmore MJ, Garnham J, Duffy A et al.:
Phenotypic spectra of bipolar disorder in
responders to lithium versus lamotrigine. Bipolar
Disord 5:110-114, 2003.
Patocka J, Klar I, Strunecka A: Molekularni
mechanismy biologickeho ucinku lithia. Cs
Fyziol 51:122-129, 2002.
Pei JJ, Tanaka T, Tung YC et al.: Distribution,
levels, and activity of glycogen synthase kinase-3
in the Alzheimer disease brain. J Neuropathol
Exp Neurol 56:70-78, 1997.
Perez M, Hernandez F, Lim F, Diaz-Nido J,
Avila J: Chronic lithium treatment decreases
mutant tau protein aggregation in a transgenic
mouse model. J Alzheimers Dis 5:301-308, 2003.
Phiel CJ, Wilson CA, Lee VM, Klein PS:
GSK-3alpha regulates production of Alzheimer's
disease amyloid-beta peptides. Nature 423:435-439, 2003.
Phiel CJ and Klein PS: Molecular targets of
lithium therapy. Annu Rev Pharmacol Toxicol
41:789-813, 2001.
Pieri-Balandraud N, Hugueny P, Henry JF,
Tournebise H, Dupont C: Hyperparathyroidism
induced by lithium. A new case. Rev Med
Interne 22:460-464, 2001.
Plenge P: Lithium effects on brain energy
metabolism. In: Gabay S, Harris J, Ho BT
(eds.): Metal Ions in Neurology and Psychiatry,
Alan R Liss, Inc. New York 1985, pp. 153-164.
Price LH and Heninger GR: Lithium in the
treatment of mood disorders. Drug Therapy 331:591-598, 1994.
Rana RS and Hokin LE: Role of
phosphoinositides in transmembrane signaling.
Physiol Rev 70:115-164, 1990.
Selkoe DJ: Notch and presenilins in vertebrates
and invertebrates: implications for neuronal
development and degeneration. Curr Opin
Neurobiol 10:50-57, 2000.
Schou M: Biology and pharmacology of lithium
ion. Pharmacol Rev 9:17-58, 1957.
Schou M: Clinical aspects of lithium in psychiatry.
In: Birch NJ (ed): Lithium and the Cell.
Orlando, Fla: Academic Press Onc. 1-6, 1991.
Schou M, Juel-Nielsen N, Stromgren E, Voldby
H. The treatment of manic psychoses by the
administration of lithium salts. J Neurol
Neurosurg Psychiatry 17:250-260, 1954.
Schrauzer GN: Lithium: occurrence, dietary
intakes, nutritional essentiality. J Am Coll
Nutr 21:14-21, 2002.
Shaldubina A, Agam G, Belmaker RH: The
mechanism of lithium action: state of the art, ten
years later. Prog Neuropsychopharmacol Biol
Psychiatry 25:855-866, 2001.
Sherman WR, Gish BG, Honchar MP,
Munsell LY : Effects of lithium on
phosphoinositide metabolism in vivo. Federation
Proc 45:2639-2646, 1986.
Sjoholt G, Guldbransen AK, Lovlie R et al.:
A human myo-inositol monophosphatase gene
(IMPA2) localized in a putative susceptibility
region for bipolar disorder on chromosome
18p11.2: genomic structure and polymorphism
screening in manic-depressive patients. Mol
Psychiatry 5:172-180, 2000.
Soares JC, Mallinger AG, Dippold CS et al.:
Effects of lithium on platelet membrane
phosphoinositides in bipolar disorder patients:
a pilot study. Psychopharmacol 149:12-16, 2000.
Sperber BR, Leight S, Goedert M, Lee VMY:
Glycogen synthase kinase 3beta phosphorylates tau
protein at multiple sites in intact cells. Neurosci
Lett 197:149-153, 1995.
Stambolic V, Ruel L, Woodgett J: Lithium
inhibits glycogen synthase kinase-3 activity and
mimics wingless signaling in intact cells. Curr
Biol 6:1664-1668, 1997.
Strunecka A and Patocka J: Lithium
a Alzheimerova choroba. Psychiatrie 8:11-14, 2004.
Strunecka A, Ripova D, Haskovec L:
Incorporation of 32P-orthophosphate into
phosphoinositides in platelets of depressive
patients before and after 10-day lithium
administration. Med Sci Res 15:197-198, 1987.
Su Y, Ryder J, Li B et al.: Lithium, a common
drug for bipolar disorder treatment, regulates
amyloid-beta precursor protein processing.
Biochemistry 43:6899-6908, 2004.
Takashima A, Murayama M, Murayama O et al.:
Presenilin 1 associates with glycogen synthase
kinase-3beta and its substrate tau. Proc Natl
Acad Sci USA 95:9637-9641, 1998.
Tosteson D.S.: Lithium and mania. Sci. Amer. 244:
130-140, 1981.
Turecki G, Grof P, Grof E et al.: Mapping
susceptibility genes for bipolar disorder: a
pharmacogenetic approach based on excellent
response to lithium. Mol Psychiatry 6:570-578, 2001.
Wikramanayake AH, Hong M, Lee PN et al.:
An ancient role for nuclear beta-catenin in the
evolution of axial polarity and germ layer
segregation. Nature 426:446-450, 2003.
Williams RS, Cheng L, Mudge
AW, Harwood AJ: A common mechanism of
action for three mood-stabilizing drugs. Nature
417:292-295, 2002.
Williams R, Ryves WJ, Dalton EC et al.:
A molecular cell biology of lithium. Biochem
Soc Trans Pt 5:799-802, 2004.
Woodget JR: Physiological roles of glycogen
synthase kinase-3: potential as a therapeutic
target for diabetes and bipolar disorder. Curr
Drug Targets Immun Endocr Metabol Disord
3:281-290, 2003.
Yu G, Chen F, Levesque G et al.: The presenilin
1 protein is a component of a high molecular
weight intracellular complex that contains betacatenin.
J Biol Chem 273:16470-16475, 1998.
Yung CY: A review of clinical trials of lithium in
neurology. Pharmacol Biochem Behav 21
Suppl 1:57-64, 1984.
|
CITED
Russell P, Williams A, Abbott A, Chadwick J, Ehya F, Flores R, Hardamon C. Effect of lithium salts on lactate dehydrogenase, adenylate kinase, and
1-phosphofructokinase activities. J Enzyme Inhib Med Chem. 25: 551-556, 2010.
Strunecka A, Patocka J. Guide for traveling through phosphoinositide pathway [Pruvodce na cestu po fosfoinozitidove draze]. Psychiatrie. 11: 8-12,
2007.
Patocka J, Strunecka A. Insulin and memory [Inzulin a pamet]. Psychiatrie. 11: 18-20, 2007.
Strunecka A, Grof P. The role of glucose in the pathogenesis of Alzheimer's disease revisited: What does it tell us about the therapeutic use of
lithium? Cent Nerv Syst Agents Med Chem. 6: 175-192, 2006.
|
